Alberto Lorenzatti

6PUBLICATIONS
17CO-AUTHORS
Haematological tumoursEpigenetics (incl. genome methylation and epigenomics)Behavioural epidemiologyCancer therapy (excl. chemotherapy and radiation therapy)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 11, 2026
Early Versus Late Initiation of Evolocumab and Arterial Aneurysm Events: An Analysis of FOURIER and FOURIER-OLE.

|Mar 20, 2026
ANGPTL3 Gene Editing: Promise and Prudence.

Alberto Juan Lorenzatti

|May 04, 2021
Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.

Alberto J Lorenzatti, Maria Laura Monsalvo, J Antonio G López

|Mar 10, 2019
Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre-specified analysis of the Chinese population from the BERSON clinical trial.

Yundai Chen, Zuyi Yuan, Juming Lu

|Mar 02, 2019
Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial.

Alberto J Lorenzatti, Freddy G Eliaschewitz, Yundai Chen

|Jul 03, 2018
Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial.

Alberto J Lorenzatti, Freddy G Eliaschewitz, Yundai Chen

Pageof 1

Frequent Collaborators

1 joint publications

Yundai Chen

1 joint publications

Andre Zimerman

1 joint publications

Michelle L O'Donoghue

1 joint publications

Robert P Giugliano